Cargando…
Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma
PURPOSE: To enhance prognostic information of protein biomarkers for clear cell renal cell carcinomas (ccRCCs), we analyzed them within prognostic groups of ccRCC harboring different tumor characteristics of this clinically and molecularly heterogeneous tumor entity. METHODS: Tissue microarrays from...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014363/ https://www.ncbi.nlm.nih.gov/pubmed/24833908 http://dx.doi.org/10.2147/OTT.S59983 |
_version_ | 1782315156497235968 |
---|---|
author | Weber, Thomas Meinhardt, Matthias Zastrow, Stefan Wienke, Andreas Erdmann, Kati Hofmann, Jörg Fuessel, Susanne Wirth, Manfred P |
author_facet | Weber, Thomas Meinhardt, Matthias Zastrow, Stefan Wienke, Andreas Erdmann, Kati Hofmann, Jörg Fuessel, Susanne Wirth, Manfred P |
author_sort | Weber, Thomas |
collection | PubMed |
description | PURPOSE: To enhance prognostic information of protein biomarkers for clear cell renal cell carcinomas (ccRCCs), we analyzed them within prognostic groups of ccRCC harboring different tumor characteristics of this clinically and molecularly heterogeneous tumor entity. METHODS: Tissue microarrays from 145 patients with primary ccRCC were immunohistochemically analyzed for VHL (von Hippel-Lindau tumor suppressor), Ki67 (marker of proliferation 1), p53 (tumor protein p53), p21 (cyclin-dependent kinase inhibitor 1A), survivin (baculoviral IAP repeat containing 5), and UEA-1 (Ulex europaeus agglutinin I) to assess microvessel-density. RESULTS: When analyzing all patients, nuclear staining of Ki67 (hazard ratio [HR] 1.08, 95% confidence interval [CI] 1.04–1.12) and nuclear survivin (nS; HR 1.04, 95% CI 1.01–1.08) were significantly associated with disease-specific survival (DSS). In the cohort of patients with advanced localized or metastasized ccRCC, high staining of Ki67, p53 and nS predicted shorter DSS (Ki67: HR 1.07, 95% CI 1.02–1.11; p53: HR 1.05, 95% CI 1.01–1.09; nS: HR 1.08, 95% CI 1.02–1.14). In organ-confined ccRCC, patients with high p21-staining had a longer DSS (HR 0.96, 95% CI 0.92–0.99). In a multivariate model with stepwise backward elimination, tumor size and p21-staining showed a significant association with DSS in patients with “organ-confined” ccRCCs. The p21-staining increased the concordance index of tumor size from 0.75 to 0.78. In patients with “organ-confined” ccRCC, no disease-related deaths occurred in the group with p21-expression below the threshold of 32.5% p21-positive cells (log rank test: P=0.002). CONCLUSION: The prognostic information of the studied protein biomarkers depended on anatomic tumor stages, which displayed different acquired biological tumor characteristics. Analysis of prognostic factors within different clinical ccRCC groups could help to enhance their prognostic power. The p21-staining was an independent prognostic factor and increased prognostic accuracy in a predictive model in “organ-confined” ccRCC. |
format | Online Article Text |
id | pubmed-4014363 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-40143632014-05-15 Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma Weber, Thomas Meinhardt, Matthias Zastrow, Stefan Wienke, Andreas Erdmann, Kati Hofmann, Jörg Fuessel, Susanne Wirth, Manfred P Onco Targets Ther Original Research PURPOSE: To enhance prognostic information of protein biomarkers for clear cell renal cell carcinomas (ccRCCs), we analyzed them within prognostic groups of ccRCC harboring different tumor characteristics of this clinically and molecularly heterogeneous tumor entity. METHODS: Tissue microarrays from 145 patients with primary ccRCC were immunohistochemically analyzed for VHL (von Hippel-Lindau tumor suppressor), Ki67 (marker of proliferation 1), p53 (tumor protein p53), p21 (cyclin-dependent kinase inhibitor 1A), survivin (baculoviral IAP repeat containing 5), and UEA-1 (Ulex europaeus agglutinin I) to assess microvessel-density. RESULTS: When analyzing all patients, nuclear staining of Ki67 (hazard ratio [HR] 1.08, 95% confidence interval [CI] 1.04–1.12) and nuclear survivin (nS; HR 1.04, 95% CI 1.01–1.08) were significantly associated with disease-specific survival (DSS). In the cohort of patients with advanced localized or metastasized ccRCC, high staining of Ki67, p53 and nS predicted shorter DSS (Ki67: HR 1.07, 95% CI 1.02–1.11; p53: HR 1.05, 95% CI 1.01–1.09; nS: HR 1.08, 95% CI 1.02–1.14). In organ-confined ccRCC, patients with high p21-staining had a longer DSS (HR 0.96, 95% CI 0.92–0.99). In a multivariate model with stepwise backward elimination, tumor size and p21-staining showed a significant association with DSS in patients with “organ-confined” ccRCCs. The p21-staining increased the concordance index of tumor size from 0.75 to 0.78. In patients with “organ-confined” ccRCC, no disease-related deaths occurred in the group with p21-expression below the threshold of 32.5% p21-positive cells (log rank test: P=0.002). CONCLUSION: The prognostic information of the studied protein biomarkers depended on anatomic tumor stages, which displayed different acquired biological tumor characteristics. Analysis of prognostic factors within different clinical ccRCC groups could help to enhance their prognostic power. The p21-staining was an independent prognostic factor and increased prognostic accuracy in a predictive model in “organ-confined” ccRCC. Dove Medical Press 2014-05-02 /pmc/articles/PMC4014363/ /pubmed/24833908 http://dx.doi.org/10.2147/OTT.S59983 Text en © 2014 Weber et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Weber, Thomas Meinhardt, Matthias Zastrow, Stefan Wienke, Andreas Erdmann, Kati Hofmann, Jörg Fuessel, Susanne Wirth, Manfred P Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma |
title | Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma |
title_full | Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma |
title_fullStr | Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma |
title_full_unstemmed | Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma |
title_short | Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma |
title_sort | stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014363/ https://www.ncbi.nlm.nih.gov/pubmed/24833908 http://dx.doi.org/10.2147/OTT.S59983 |
work_keys_str_mv | AT weberthomas stagedependentprognosticimpactofmolecularsignaturesinclearcellrenalcellcarcinoma AT meinhardtmatthias stagedependentprognosticimpactofmolecularsignaturesinclearcellrenalcellcarcinoma AT zastrowstefan stagedependentprognosticimpactofmolecularsignaturesinclearcellrenalcellcarcinoma AT wienkeandreas stagedependentprognosticimpactofmolecularsignaturesinclearcellrenalcellcarcinoma AT erdmannkati stagedependentprognosticimpactofmolecularsignaturesinclearcellrenalcellcarcinoma AT hofmannjorg stagedependentprognosticimpactofmolecularsignaturesinclearcellrenalcellcarcinoma AT fuesselsusanne stagedependentprognosticimpactofmolecularsignaturesinclearcellrenalcellcarcinoma AT wirthmanfredp stagedependentprognosticimpactofmolecularsignaturesinclearcellrenalcellcarcinoma |